Related Experiment Video

Updated: May 29, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

EGFR-targeted therapy

Loredana Vecchione1, Bart Jacobs, Nicola Normanno

  • 1Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49 bus 602 Be 3000, Leuven, Belgium. loredana_vecchione@hotmail.com

Experimental Cell Research
|September 20, 2011
PubMed

Insights

Targeted anti-Epidermal Growth Factor Receptor (EGFR) therapies offer new cancer treatments. Understanding tumor resistance is key to developing personalized medicine for colorectal cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Anti-Epidermal Growth Factor Receptor (EGFR) therapies represent a significant advancement in cancer treatment.
  • Initial understanding of molecular mechanisms driving tumor sensitivity and resistance to these targeted agents was limited.
  • Colorectal cancer is a primary focus for evaluating anti-EGFR therapies.

Purpose of the Study:

  • To review current knowledge on molecular bases of tumor sensitivity and resistance to anti-EGFR inhibitors.
  • To assess progress in developing personalized cancer therapy using anti-EGFR treatments.
  • To identify future challenges in the field of targeted cancer therapy.

Main Methods:

  • Literature review of studies on anti-EGFR therapies in colorectal cancer.
  • Analysis of molecular mechanisms of sensitivity and resistance.
  • Synthesis of current advancements in personalized medicine.

Main Results:

  • Significant progress has been made in understanding the molecular underpinnings of anti-EGFR therapy response.
  • Identification of biomarkers is crucial for predicting patient outcomes.
  • Personalized treatment strategies are emerging based on individual tumor molecular profiles.

Conclusions:

  • Continued research into molecular mechanisms is essential for optimizing anti-EGFR therapy.
  • Personalized medicine approaches hold great promise for improving efficacy and reducing toxicity.
  • Addressing challenges in resistance mechanisms will be critical for future therapeutic development.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: